Genetically engineered natural killer (NK) cell immunotherapy for children poor risk b-cell (CD20+) leukemia and lymphoma (L/L).

被引：0
|
作者：
Chu, Yaya [1 ]
Ayello, Janet [1 ]
Hochberg, Jessica [1 ]
Van de Ven, Carmella [1 ]
Murphy, James [1 ]
Cairo, Mitchell S. [1 ]
机构：
[1] New York Med Coll, Valhalla, NY 10595 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13022
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Genetically engineered natural killer (NK) cell immunotherapy for poor risk B-cell (CD20+) leukemia and lymphoma (L/L)
    Chu, Yaya
    Ayello, Janet
    Hochberg, Jessica
    Murphy, James
    Stier, Andrew
    Cairo, Mitchell S.
    CANCER RESEARCH, 2012, 72
  • [2] Genetically Engineered Natural Killer (NK) Cell Immunotherapy for Poor Risk B-Cell (CD20+) Leukemia and Lymphoma
    Chu, Yaya
    Ayello, Janet
    Hochberg, Jessica
    vandeVen, Carmella
    Murphy, James
    Stier, Andrew
    Cairo, Mitchell S.
    BLOOD, 2011, 118 (21) : 458 - 459
  • [3] Expanded Natural Killer (NK) Cells Transfected with Anti-CD20 Chimeric Antigen Receptor (CAR) mRNA Have Significant Cytotoxicity Against Poor Risk B-Cell (CD20+) Leukemia/Lymphoma (B-L/L)
    Chu, Yaya
    Ayello, Janet
    Lo, Lowrence
    Katz, Jared
    Yahr, Ashlin
    Hochberg, Jessica
    van de Ven, Carmella
    Zhou, Xianzheng
    Cairo, Mitchell S.
    BLOOD, 2012, 120 (21)
  • [4] Immunotherapy of B-cell malignancies with genetically engineered human CD8+ natural killer T cells
    M Pieper
    C Scheffold
    S Duwe
    C Rossig
    G Bisping
    M Stelljes
    T F Tedder
    H Jurgens
    W E Berdel
    J Kienast
    Leukemia, 2006, 20 : 729 - 732
  • [5] Immunotherapy of B-cell malignancies with genetically engineered human CD8+ natural killer T cells
    Pieper, M
    Scheffold, C
    Duwe, S
    Rossig, C
    Bisping, G
    Stelljes, M
    Tedder, TF
    Jurgens, H
    Berdel, WE
    Kienast, J
    LEUKEMIA, 2006, 20 (04) : 729 - 732
  • [6] Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20+ B-cell lymphoma
    Wendy K. Nevala
    John T. Butterfield
    Shari L. Sutor
    Daniel J. Knauer
    Svetomir N. Markovic
    Scientific Reports, 7
  • [7] Enhanced Targeting B Cell Lymphoma/Leukemia (B-L/L) by Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer (NK) Cells Combined with a Histone Deacetylase Inhibitor, Romidepsin
    Chu, Yay
    Yahr, Ashlin
    Lo, Lowrence
    Ayello, Janet
    Katz, Jared
    Cairo, Mitchell S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S313 - S314
  • [8] Guideline for radioimmunotherapy of CD20+ follicular B-cell non-Hodgkin's lymphoma
    Fischer, M.
    Gruenwald, F.
    Knapp, W. H.
    Truemper, L.
    von Schilling, C.
    Dreyling, M.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2009, 48 (06): : 215 - 220
  • [9] Expression of B-cell intracellular signaling molecules in CD20+ classical Hodgkin's lymphoma
    Chiu, A
    Hyjek, E
    Chadburn, A
    Frizzera, G
    MODERN PATHOLOGY, 2005, 18 : 226A - 226A
  • [10] Expression of B-cell intracellular signaling molecules in CD20+ classical Hodgkin's lymphoma
    Chiu, A
    Hyjek, E
    Chadburn, A
    Frizzera, G
    LABORATORY INVESTIGATION, 2005, 85 : 226A - 226A
12345